ImmuPharma PLC Email Format

Biotechnology ResearchEngland, United Kingdom2-10 Employees

ImmuPharma PLC is a biotechnology research company focused on discovering and developing peptide-based therapeutics. Its lead program, P140, is described as an immune tolerance restorer for autoimmune conditions such as systemic lupus erythematosus and chronic inflammatory demyelinating polyneuropathy, with preclinical models suggesting potential activity across other diseases sharing the same mechanism. The company operates in the specialty biopharmaceutical space, pursuing novel peptide therapeutics for autoimmune diseases and anti-infectives, with a portfolio that reflects this focus.
Based in London, England, ImmuPharma positions itself within the biotechnology research sector as a company advancing a targeted autoimmune platform. Its activities encompass drug discovery and development for autoimmune indications, and it has communicated ongoing efforts around other programs, including Kapiglucagon, a prodrug aimed at addressing the growing type 1 diabetes market. The organization has engaged in updates and corporate developments in recent years, including leadership appointments and website initiatives that align with its scientific and strategic evolution.

Get verified ImmuPharma PLC emails free

Company overview Employee directory